AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 16, 2026 BVF reports Vistagen warrant-based beneficial ownership Headline · Source: SEC filing
Nasdaq: $VTGNFasedienol redesignFDA Type C feedbackFunding and listing risk

VTGN Stock Hub: Vistagen News, Fasedienol and the Funding Test

Vistagen plans to revise its next fasedienol study after FDA feedback reported on November 9. PALISADE-2 met its primary endpoint and three other Phase 3 studies missed theirs. Vistagen had $10.892 million in cash and equivalents and $9.142 million in marketable securities at September 30. The November 13 filing disclosed substantial doubt about continuing as a going concern. November 9 regulatory update · Form 10-Q for fiscal 2027 Q2.

Last updated: November 18, 2026 · Financial period: quarter ended September 30, 2026, the second quarter of fiscal 2027 · Currency: USD
Full research report · PDF
Vistagen Therapeutics, Inc. ($VTGN), research updated November 12, 2026
15 pages covering the November 9, 2026 Type C meeting outcome and the October 26 workforce reduction, the fasedienol program and its trial history, the pipeline, June cash and dilution, ownership, risks, scenarios, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next dated checkpoint · Nasdaq compliance
February 1, 2027 · Extended minimum-bid deadline

Nasdaq granted Vistagen an extension to regain compliance. The separate clinical milestones are a revised protocol, financing and any trial start. August 4 extension notice · November 9 study update.

Latest: Two November 16 Schedule 13G amendments, from BVF Partners and Commodore Capital, report September 30 beneficial ownership based on warrant shares. BVF filing · Commodore filing.
Vistagen Therapeutics, Inc. VTGN daily stock chart
Daily chart $VTGN. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

VTGN stock at a glance

Chart analysis · JC
Technical chart analysis of $VTGN with bull and bear scenarios on JC Just Charts.
Cash and securities · September 30
$20.034M
Merlintrader calculation: $10.892M cash and equivalents plus $9.142M marketable securities on September 30. September balance sheet.
Quarterly operating cash flow
−$12.163M
Merlintrader calculation: $26.870M used over six months less $14.707M used in the June quarter. September filing · June filing.
September-quarter revenue
$0.138M
Sublicense and other revenue, rather than product sales; $1.614M in the six months to September 30. Clinical-development spending and financing requirements remain separate. Source: SEC.
Basic shares · November 10
46.186M
46,186,049 shares outstanding on the cover of the Form 10-Q filed November 13; 44,376,911 on August 10. This dated denominator does not include every potential future equity issuance. Source: SEC.
PALISADE Phase 3 primary endpoints
1 of 4 met
PALISADE-2 met its primary endpoint with 141 randomized participants; PALISADE-1, -3 and -4 did not. The count is not an approval probability. Source: SEC; Source: PALISADE-2 results.
Shares short · October 30 settlement
2.488M
2,488,148 shares short, average daily volume of 728,036 and 3.42 days to cover. October 30 settlement data.

Where Vistagen stands now

The November 9 regulatory update describes a planned revised protocol for fasedienol in the general adult social anxiety disorder population. Vistagen plans to evaluate overall symptoms with the Liebowitz Social Anxiety Scale (LSAS) and add interim assessments. November 9 update · The regulatory and trial calendar.

The quarter ended September 30, 2026, the second quarter of fiscal 2027, produced $0.138 million of sublicense and other revenue and a $10.740 million net loss. Operating cash use was $26.870 million over six months. Management forecasts funding into 2027 and the filing continues to disclose substantial doubt about going concern. November 13 Form 10-Q · November 13 corporate update · Quarterly results and cash use.

Main risk: current capital resources cannot fund the next LSAS-based Phase 3 trial or further clinical development of the other pherine candidates, according to the quarterly filing. Controlled replication and additional financing remain necessary. Q2 fiscal 2027 funding-risk disclosure.

The constructive case

Merlintrader reading: a practical protocol, sufficient financing and positive controlled results would strengthen the case for further development.

The cautious case

Merlintrader reading: redesign and funding could take longer while exploratory outcomes fail to reproduce in a prospectively defined population.

Latest VTGN news

Nov 16, 2026

BVF reports Vistagen warrant-based beneficial ownership

The Schedule 13G amendment reports 1,690,014 underlying shares, or 3.7%, as of September 30. The reported shares are issuable upon exercise of warrants.

Nov 16, 2026

Commodore reports Vistagen warrant-based beneficial ownership

The Schedule 13G amendment reports 1,690,014 underlying shares, or 3.7%, as of September 30. The reported shares are issuable upon exercise of warrants.

Nov 13, 2026

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

Vistagen reported a net loss of $10.7 million for the three months ended September 30, 2026, versus $19.4 million a year earlier. R&D expense was $6.6 million, down from $15.9 million, while G&A expense was $4.5 million compared with $4.4 million. Cash, cash equivalents, and marketable securities were $20.0 million as of September 30, 2026, which the company believes will fund operations into 2027.

Nov 9, 2026

Vistagen provides regulatory update following Type C meeting with FDA on fasedienol

Vistagen reported FDA feedback from a Type C meeting on potential registrational paths for fasedienol in social anxiety disorder (SAD). The FDA gave feedback on the proposed use of the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint in a future Phase 3 study in adults with SAD, including recommendations on interim assessments. Vistagen plans to include interim assessments using eDiaries and qualitative patient surveys, submit a revised protocol to the FDA, and focus future development on the general SAD population.

Nov 3, 2026

PALISADE-3 Phase 3 fasedienol trial status updated to completed

The study status for the Phase 3 trial of fasedienol nasal spray for acute treatment of anxiety in adults with social anxiety disorder (PALISADE-3, NCT06358651) was updated to COMPLETED. The record lists a completion date of 2026-07-13 and an enrollment of 238. The record update was posted 2026-11-03, and VistaGen Therapeutics, Inc. is the lead sponsor.

Oct 30, 2026

Vistagen reduces workforce by approximately 31%

Vistagen implemented a board-approved workforce reduction on October 26 while retaining core capabilities for its clinical-stage priorities. The company estimates approximately $1.0 million in severance and termination costs and expects approximately $3.2 million in annual salary and benefits savings; actual amounts may differ. The action does not establish funding or regulatory agreement for a Phase 3 trial.

VTGN stock catalysts and dated watchpoints

  • October 26–30, 2026 — Vistagen implemented a workforce reduction and disclosed estimated severance costs and annual savings. Company disclosure October 30 Form 8-K.
  • November 3–4, 2026 — Registry records for PALISADE-3, PALISADE-4 and the repeat-dose study list the studies as completed. These are status updates. Registry records PALISADE-3 · PALISADE-4 · Repeat-dose study.
  • November 9, 2026 — Vistagen reported Type C feedback and plans to add interim assessments in its next protocol. Regulatory discussion reported November 9 Form 8-K exhibit.
  • November 13, 2026 — Vistagen filed fiscal 2027 second-quarter results and issued a corporate update. Results reported Fiscal 2027 Q2 Form 10-Q · Company update.
  • November 16, 2026 — BVF and Commodore filed ownership amendments for their own warrant interests as of September 30. Dated ownership disclosures BVF Schedule 13G/A · Commodore Schedule 13G/A.
  • February 1, 2027 — Extended Nasdaq minimum-bid compliance deadline. Listing deadline August 4 extension notice.
  • Timing unannounced — Revised Phase 3 protocol submission and trial funding. Company plan November 9 update.

Fasedienol after the four PALISADE trials

PALISADE-2 met its primary endpoint. PALISADE-1, PALISADE-3 and PALISADE-4 missed theirs. The separate post-hoc and open-label findings inform hypotheses for controlled testing. Quarterly filing and trial overview · Controlled PALISADE trials · Exploratory subgroups.

The November update sets out the planned revisions to the next protocol. November 9 update · Regulatory calendar.

Cash runway and conditional financing capacity

The September filing covers cash, securities and active equity sales. It identifies substantial doubt about going concern. The October workforce reduction carries estimated severance costs and projected annual savings. September financial statements and liquidity note · October workforce disclosure · Financial position and expenses.

Vistagen had 46,186,049 outstanding shares on November 10. Warrants and future share sales affect dilution and depend on different terms. Financing and warrant terms · Shares and awards.

Vistagen Therapeutics deep dive: the full analysis

The fasedienol evidence, proposed next study and financing requirements: a full analysis of Vistagen’s clinical record, broader pipeline and capital structure. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Bull, base and bear scenarios

Bull case: a revised prospective study demonstrates useful benefit

The constructive case requires a workable new fasedienol trial, financing to conduct it and a reproducible controlled treatment effect. The company’s November 9 FDA update concerns a potential LSAS-based Phase 3 study for overall treatment of the general social-anxiety-disorder population. It plans a revised protocol, rather than announcing a finalized agency-approved study or enrollment start. Merlintrader reading: the opportunity lies in prospectively testing the proposed treatment model, not converting a favorable subgroup or open-label trajectory into a completed registrational result. November 9, 2026 FDA meeting update September 30, 2026 Form 10-Q, Q2 fiscal 2027

PALISADE-2 supplies a positive randomized signal, while PALISADE-1, -3 and -4 did not meet their primary efficacy endpoints. A new study could address a different treatment duration and broader functional outcome. Merlintrader reading: favorable replication would strengthen the case if its population, endpoint and analysis were specified prospectively and the benefit justified treatment burden. A revised questionnaire or hypothesis is not evidence of success by itself. PALISADE-2 registry and posted results December 17, 2025 PALISADE-3 result disclosure September 30, 2026 Form 10-Q, Q2 fiscal 2027

Base case: planning advances while evidence and funding remain unresolved

The central scenario includes additional protocol work and regulatory interaction, with no announced new-study readout date. The company’s September resources are limited and its November filing retains going-concern doubt. The October workforce reduction aims to lower costs, but those savings are estimates and coexist with implementation costs. Merlintrader reading: extending the planning period can preserve options while ongoing expenses continue to consume cash. Clinical and financing progress need to be assessed together. September 30, 2026 Form 10-Q, Q2 fiscal 2027 November 13, 2026 financial and business update

The broader pherine pipeline and regional collaboration rights provide additional possibilities, each with its own evidence and resource requirements. Merlintrader reading: a portfolio may offer alternative development paths without making each path affordable at the same time. A small positive exploratory study in another condition cannot resolve the failed fasedienol comparisons or fund a new Phase 3 program. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Bear case: the next study is unworkable, unsuccessful or underfunded

The adverse scenario involves further evidence requirements, a trial that cannot be financed on workable terms, another unsuccessful controlled comparison or listing difficulties. A financing could extend operations while materially changing common-share participation. Merlintrader reading: the available cash and prior safety experience reduce only particular risks; they do not guarantee clinical effectiveness, regulatory agreement or sustained access to capital. September 30, 2026 Form 10-Q, Q2 fiscal 2027

What would falsify this reading

Prospective controlled evidence could strengthen the assessment. A reproducible benefit on a prespecified primary outcome in the intended population would address the central clinical uncertainty. A further uncontrolled improvement would provide descriptive information while leaving the placebo-adjusted question open. September 30, 2026 Form 10-Q, Q2 fiscal 2027 November 9, 2026 FDA meeting update

Concrete financing could change the resource outlook. Received proceeds or a binding, funded development agreement could reduce the near-term constraint. The amount, restrictions, trial budget and rights transferred would determine how much operating flexibility the transaction provides. Nominal offering capacity and conditional milestones have a different status. September 30, 2026 Form 10-Q, Q2 fiscal 2027

A new failure or unworkable protocol could weaken the case. Additional randomized disappointment, agency requirements that cannot be met economically or inability to fund the program would alter the development path. Merlintrader reading: the useful evidence is what the new study and financing actually establish, rather than a retrospective selection of the best earlier percentage. Listing compliance also requires its own documented outcome. September 30, 2026 Form 10-Q, Q2 fiscal 2027

02 The company and the proposed nasal-neurocircuitry mechanism

Vistagen is a clinical-stage neuroscience company developing intranasal compounds called pherines. Its most advanced candidate is fasedienol for social anxiety disorder. Other programs include refisolone, itruvone, PH15 and PH284. AV-101 is a separate oral asset. None of these candidates is an approved Vistagen product generating commercial drug sales. The company’s reported licensing revenue follows partner-contract accounting rather than an established prescription business. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The proposed pherine mechanism involves peripheral nasal chemosensory receptors and downstream neural circuits, without requiring systemic absorption or entry into the brain to achieve the intended effect. This is the company’s development rationale. Comparative effectiveness and safety require adequate controlled evidence in the intended patient population. Drug mechanism, observed pharmacology, clinical benefit and regulatory approval are different levels of evidence. September 30, 2026 Form 10-Q, Q2 fiscal 2027

A small mechanistic experiment in healthy volunteers evaluated physiological responses to pherine exposure. It was not a social-anxiety efficacy trial. Merlintrader reading: such work can inform biological hypotheses while leaving patient benefit, durability and uncommon risks unresolved. The stock’s principal clinical question is whether the intended treatment produces useful improvement beyond placebo in a prospectively defined study. 2024 exploratory mechanistic publication September 30, 2026 Form 10-Q, Q2 fiscal 2027

The latest development proposal also changes the question being tested. Earlier Phase 3 trials centered on distress during a clinic-based public-speaking challenge. The prospective plan focuses on overall social-anxiety treatment and functional change over time, with LSAS and interim patient assessments. These are related concepts, while a positive result under one design cannot be assumed under the other. November 9, 2026 FDA meeting update

Merlintrader reading: the company combines an unconventional mechanistic approach, substantial exposure experience and an inconsistent controlled efficacy record. Its operating model still requires external funding and execution through contractors, sites and regulatory work. A platform narrative becomes more informative when it is connected to a specified study, an adequate budget and evidence that the selected compound works in the population for which approval would be sought. September 30, 2026 Form 10-Q, Q2 fiscal 2027

03 The November FDA feedback and the prospective development calendar

On November 9, 2026, Vistagen reported FDA Type C feedback on a potential fasedienol Phase 3 study in adults with social anxiety disorder. According to the company, the feedback included recommendations regarding LSAS as the primary endpoint and interim assessments to examine whether acute effects could lead to longer-term functional improvement. The company plans to revise and submit its protocol. Feedback is a completed interaction; the revised prospective trial remains a future step. November 9, 2026 FDA meeting update

The latest plan concerns the general social-anxiety population and overall treatment, rather than only acute treatment or an exclusively very-severe population. Electronic diaries and qualitative patient surveys are planned interim assessments. An interim patient measure, the primary endpoint and an exploratory subgroup each have different statistical roles. The previously reported severe-patient findings remain hypotheses rather than a substitute for testing the intended general population. September 30, 2026 Form 10-Q, Q2 fiscal 2027 November 9, 2026 FDA meeting update

The September presentation’s earlier protocol proposal described a specific size and treatment duration. The November feedback now precedes a revised submission. Merlintrader reading: the decisive operational developments would be a finalized protocol, adequate financing and an actual start, with any subsequent readout window tied to enrollment and follow-up. No accepted New Drug Application (NDA) or Prescription Drug User Fee Act (PDUFA) goal date follows from the Type C meeting. The publication of a proposed design is also different from a registered trial already dosing patients. November 9, 2026 FDA meeting update September 30, 2026 Form 10-Q, Q2 fiscal 2027

The company closed PALISADE-3 and -4 extensions in July 2026 and the repeat-dose extension in August for business reasons after evaluating its safety exposure. Those closures are completed study decisions. They do not create another future placebo-controlled readout from those open-label cohorts. Continued analysis can provide information, while the clinical significance depends on the design and populations that produced the observations. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The financial calendar includes the fiscal year ending March 31, 2027 and a February 1, 2027 Nasdaq compliance deadline. The report filed November 13 covers the quarter ended September 30, the second quarter of fiscal 2027. Merlintrader reading: reporting periods, clinical development milestones and exchange deadlines address different risks. None sets the outcome or timing of the others. September 30, 2026 Form 10-Q, Q2 fiscal 2027

04 The four randomized PALISADE trials

The Phase 3 PALISADE program used a public-speaking challenge and a patient-rated 0–100 Subjective Units of Distress Scale, or SUDS, as its primary efficacy framework. The controlled comparison is the treatment effect relative to placebo, rather than improvement in the active group alone. The study results differ, and the positive PALISADE-2 outcome belongs beside the three unsuccessful primary comparisons. PALISADE-1 registry and posted results PALISADE-2 registry and posted results December 17, 2025 PALISADE-3 result disclosure September 30, 2026 Form 10-Q, Q2 fiscal 2027

Study and reported populationPrimary efficacy outcomePrimary source
PALISADE-1: 224 randomized; registry results posted September 12, 2025Did not meet; p=0.5063PALISADE-1 registry and posted results
PALISADE-2: 141 randomized; primary results August 7, 2023Met; adjusted SUDS contrast −5.8 points, p=0.0153PALISADE-2 registry and posted results August 7, 2023 PALISADE-2 primary results
PALISADE-3: 238 participants; results December 17, 2025Did not meet; reported improvements 13.6 versus 14.0 pointsDecember 17, 2025 PALISADE-3 result disclosure
PALISADE-4: 238 participants; results June 30, 2026Did not meet; reported changes −9.5 versus −11.4 points, p=0.427June 30, 2026 PALISADE-4 primary results

PALISADE-2 did not reach its originally planned 208 randomized participants. It stopped with 141 after the program pause and the company’s evaluation of the path forward. The registry’s larger initial enrollment includes participants who were not subsequently randomized. The 70-person and 71-person randomized groups form the reported efficacy population. Enrollment, run-in participation and randomized analysis are distinct denominators. PALISADE-2 registry and posted results

Merlintrader reading: the early stop and smaller population belong in the interpretation without mathematically erasing the reported significant result. Equally, that one positive comparison does not make the subsequent negative studies positive. Different trial conditions and analysis details prevent a simple addition of participants from becoming a valid pooled treatment-effect estimate. PALISADE-2 registry and posted results December 17, 2025 PALISADE-3 result disclosure September 30, 2026 Form 10-Q, Q2 fiscal 2027

PALISADE-4 illustrates why within-group improvement is insufficient: symptoms improved in both arms, with the reported placebo change larger on the primary comparison. The later selected very-severe analysis asks a different question. Merlintrader reading: the forward development case requires a prospectively defined study that reproduces a clinically useful effect, rather than relabeling the full-population result using a more favorable subset. June 30, 2026 PALISADE-4 primary results September 30, 2026 Form 10-Q, Q2 fiscal 2027

Official registry updates posted November 3 and 4 list PALISADE-3, PALISADE-4 and the repeat-dose study as completed, with 238, 238 and 61 actual participants respectively. Their final study-completion dates are July 13, July 14 and August 26, 2026. Those records do not contain posted results sections. These November entries are administrative study updates, separate from the earlier issuer announcements of efficacy results and the different safety populations in the extensions. PALISADE-3 registry updated November 3, 2026 PALISADE-4 registry updated November 4, 2026 Repeat-dose registry updated November 4, 2026

A separate randomized Phase 2A study in adjustment disorder with anxiety enrolled 41 participants, 19 active and 22 placebo. Results posted February 5, 2026 show that the 28-day Hamilton Anxiety Scale (HAM-A) primary comparison was not significant: changes −12.5 versus −12.6, p=0.9338. This is a different diagnosis and endpoint from the social-anxiety-disorder speaking-challenge program, rather than another PALISADE trial or a new LSAS Phase 3 result. February 5, 2026 posted adjustment-disorder study results

05 Repeat dosing and the very-severe subgroups

The exploratory Phase 2 repeat-dose study included 61 participants in three randomized groups. It compared active-treatment approaches with placebo during a speaking challenge, while assessing safety and tolerability. The company reported that its safety objective was met. The overall efficacy comparison was not statistically significant, with p=0.2 in the primary analysis. The study was not designed to provide a definitive significance-powered comparison. August 6, 2026 exploratory repeat-dose results September 30, 2026 Form 10-Q, Q2 fiscal 2027

In its prespecified very-severe population, defined by baseline LSAS of at least 95, the company reported nominal p=0.05 for single dose versus placebo and p=0.04 for pooled active treatment. These values concern selected subgroup comparisons; they do not transform the overall result into a successful primary efficacy finding or establish that repeat dosing is superior to single dosing. Nominal analyses and multiplicity-controlled confirmatory tests have different evidentiary weight. August 6, 2026 exploratory repeat-dose results

The PALISADE-4 very-severe finding was post hoc, rather than the same prespecified analysis. It involved 123 participants and reported an adjusted mean contrast of −9.1 points, nominal p=0.036. Its definition includes additional exclusions: one 15-participant site disqualified after documented irregularities, five participants with high baseline SUDS scores and one with a large placebo-run-in improvement. These conditions define the published subgroup, rather than the entire randomized population. September 30, 2026 Form 10-Q, Q2 fiscal 2027 September 24, 2026 exploratory subgroup presentation

Merlintrader reading: prespecified and post-hoc analyses can both inform a hypothesis, while their status and selection rules remain important. The repeated appearance of a favorable severe-patient pattern is not independent proof of a future treatment effect. Small groups, different analysis choices and exclusions can materially affect the estimate. An adequately controlled prospective test is needed to establish whether the intended population benefits. September 30, 2026 Form 10-Q, Q2 fiscal 2027 August 6, 2026 exploratory repeat-dose results

The current FDA-feedback plan focuses on general social anxiety disorder and overall treatment rather than limiting enrollment to those historical very-severe subsets. Merlintrader reading: that choice makes the proposed treatment model broader and the prospective question more consequential. A new endpoint and repeated everyday use have to demonstrate their own result; the subgroup evidence cannot be carried over as if the new study had already met it. November 9, 2026 FDA meeting update

06 Open-label observations and the safety database

The PALISADE-4 extension enrolled 322 safety participants, with a July 24, 2026 cutoff. It was open-label and uncontrolled. The reported LSAS observations moved from a baseline mean of 99.3 in 320 participants to a mean improvement of 31.4 points among 197 month-four observations. The company reported at least a 20-point LSAS improvement in 65% of that month-four population. Those are observed open-label outcomes, not a placebo-adjusted efficacy estimate in all baseline participants. September 22, 2026 PALISADE-4 extension update

The extension reported five adverse-event discontinuations among 322 participants, or 1.6%, with none attributed to fasedienol. No drug-related serious adverse events were reported. The separate PALISADE-3 extension had a 341-person safety population and nine adverse-event discontinuations, or 2.6%, at its May 8 cutoff. Relatedness, seriousness and discontinuation are different measures. The absence of a related serious event is narrower than the absence of all adverse events or all serious events. September 22, 2026 PALISADE-4 extension update May 12, 2026 PALISADE-3 extension update

Month-four observation availability is also different from treatment retention. Some extension participants could not reach that time point before the business-driven closure. Merlintrader reading: the remaining observations may describe a trajectory while leaving expectations, selection, natural variation and other uncontrolled influences unresolved. Missing observations cannot all be classified as toxicity withdrawals, nor can the available patients be treated as a randomized confirmation of efficacy. September 30, 2026 Form 10-Q, Q2 fiscal 2027 September 22, 2026 PALISADE-4 extension update

As of May 31, the company estimated more than 1,500 people with at least one fasedienol exposure, more than 300 with six-month exposure and more than 100 with twelve-month exposure. It considered minimum International Council for Harmonisation (ICH) E1 exposure recommendations met. The current filing nevertheless states that specific patient-exposure requirements for a possible NDA have not yet been aligned with the FDA. A sponsor’s cumulative safety count and an agency determination of application sufficiency are distinct. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: safety experience can reduce particular uncertainties while leaving both efficacy and the final benefit-risk assessment open. A broad proposed mechanism and limited observed systemic exposure do not guarantee that uncommon risks will remain absent in wider use. The prospective development program needs to connect the intended treatment pattern with adequate safety evidence as well as a controlled clinical benefit. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The extension’s Social Phobia Inventory (SPIN) outcome provides another descriptive measure: baseline mean 48.5 in 321 participants, with a 14.9-point month-four improvement among 199 observations. The reported 59% threshold response concerns at least a ten-point SPIN improvement, rather than the separate LSAS twenty-point definition. Different scale thresholds and assessment counts cannot be combined into one responder rate. Merlintrader reading: consistency of uncontrolled trajectories can support a prospective question, while the randomized comparator remains necessary to estimate treatment contribution. September 22, 2026 PALISADE-4 extension update

07 The other pipeline and its separate evidence

Refisolone is being developed for menopausal vasomotor symptoms and other potential women’s-health indications. A small randomized, placebo-controlled Phase 2A study in Mexico reported fewer hot flashes, with a favorable comparison beginning in week one and continuing through four weeks. The April 2026 FDA Study May Proceed letter enables further U.S. development under an Investigational New Drug application (IND). It is permission to investigate, rather than marketing approval or proof that a new U.S. Phase 2 study has already succeeded. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The premenstrual dysphoric disorder (PMDD) work concerns a different patient group, symptom measures and study period. Merlintrader reading: an exploratory signal in premenstrual symptoms cannot supply the registrational result for vasomotor symptoms, while hot-flash, depression and social-anxiety indications each require their own evidence. Each program needs a prospectively defined route with appropriate endpoints and resources. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Itruvone is a candidate for major depressive disorder. Its historical randomized exploratory Phase 2A study in Mexico reported favorable depressive-symptom comparisons, while a U.S. Phase 1 study in 2023 provided additional safety information. The current plan contemplates further U.S. Phase 2 development under its IND. A small early efficacy result and healthy-volunteer safety study do not constitute successful late-stage treatment evidence or a completed commercial application. September 30, 2026 Form 10-Q, Q2 fiscal 2027

PH15 concerns psychomotor impairment associated with mental fatigue, while PH284 concerns cancer cachexia. Their early exploratory studies and proposed U.S. IND work are distinct from the fasedienol program. AV-101 is an oral asset for which the company does not anticipate further independent development or commercialization and is considering a potential third-party path. No funded partnership should be assumed without an actual agreement and its obligations. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: the portfolio creates choices for scientific prioritization and external partnering, while available cash limits how many programs can progress simultaneously. Success in another indication could add enterprise value, but it cannot retroactively repair a failed fasedienol primary comparison. The strongest next steps would combine interpretable data with an executable development plan and identified financing. September 30, 2026 Form 10-Q, Q2 fiscal 2027

08 Partnership economics and the GATC collaboration

AffaMed holds specified fasedienol development and commercial rights in Greater China, South Korea and named Southeast Asian territories. Vistagen retains rights in the United States and outside the licensed territory. The agreement included a $5 million upfront payment received in August 2020, with up to $172 million of conditional milestones and country-specific royalties. The maximum future payments depend on successful development and commercialization; they are not current receivables or committed trial financing. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The partner may participate in a global study under the agreement’s conditions, including specified territorial costs. Participation is a development arrangement that needs actual scope and funding, rather than an assurance that every planned trial is covered. The current reported AffaMed revenue includes recognition from previously deferred consideration. Accounting revenue and cash paid in the present quarter are different measures. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The Fuji negotiation arrangement is also distinct. A $1.5 million payment was received in 2023. The remaining approximately $1.3 million was recognized when the negotiation period ended during the six months ended September 30, 2026. The period has terminated and the performance obligation is fully satisfied, with no further revenue expected from that arrangement. The historical receipt and its revenue recognition are separate from execution of a commercialization license or receipt of fresh capital. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The October 20 GATC Health collaboration concerns protocol design, prioritization and analytical support across potential fasedienol, refisolone and itruvone work. It is a planning collaboration. It does not change the results of a human trial or turn a proposed design into an agreed FDA protocol. The announced scope does not provide a quantified funding commitment for the next study. October 20, 2026 GATC collaboration announcement September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: partnerships become economically more concrete when they identify responsibilities, usable cash, milestones and the rights transferred. Analysis that informs development can be useful while leaving the actual trial and financing decisions unresolved. Prior upfront receipts, conditional future payments and current clinical budgets therefore need separate treatment in the operating model. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The current strategic review includes potential financing, partnering and asset or company transactions, as well as further rationalization or a possible wind-down. No selected transaction or completion timetable has been announced in the November report. Merlintrader reading: those alternatives have substantially different operating and ownership consequences. A review preserves choices; it does not mean that a buyer has agreed terms, a partner has funded development or the company has decided to implement every listed option. September 30, 2026 Form 10-Q, Q2 fiscal 2027

09 Q2 fiscal 2027 financial results and going concern

The quarter ended September 30, 2026 is Vistagen’s second quarter of fiscal 2027; the fiscal year ends March 31. September cash and equivalents were $10.892 million and marketable securities $9.142 million. Merlintrader calculation: combined liquidity was $20.034 million. These reporting-date resources are separate from later ATM receipts and from the value of prepaid or other non-cash assets. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The following amounts are USD millions for the three months ended September 30, 2026. Licensing revenue does not represent sales of an approved Vistagen medicine. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Q2 fiscal 2027 measureUSD millions
Revenue0.138
Research and development6.554
General and administrative4.521
Net loss10.740

For the six months ended September 30, revenue was $1.614 million, net loss $23.770 million and operating cash use $26.870 million. The cumulative period begins April 1, 2026, rather than January. Revenue recognition includes historical partner receipts, while cash expenses and working-capital movements follow their own timing. The half-year loss is not interchangeable with the quarter’s operating cash use. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The November 13 filing concludes that substantial doubt exists about the company’s ability to continue as a going concern. The filing explicitly states that current capital resources will not suffice to fund the next fasedienol Phase 3 study with LSAS as the primary endpoint or further clinical development of the other pherine candidates. Prospective financing and partnerships remain outside the company’s full control. The statement is therefore different from a declaration that cash is secured for a new trial or for twelve months after issuance. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: the cash balance provides limited flexibility relative to the development agenda, while the cost base is changing through reductions and the closure of earlier studies. A simple historical burn multiple would not capture a new protocol, severance, financing costs or the next trial’s commitments. Actual spending, received financing and the funded scope of work will determine how much of the proposed plan can be executed. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Current assets were $22.294 million against $8.429 million current liabilities. Merlintrader calculation: working capital was $13.865 million, different from the $20.034 million cash-and-securities total. Prepaid assets and liabilities account for part of that distinction. The statements report $14.992 million stockholders’ equity; neither working capital nor equity is cash distributable to shareholders or a guaranteed value floor. September 30, 2026 Form 10-Q, Q2 fiscal 2027

In the six-month cash-flow statement, investing activities provided $5.713 million, principally through securities sales and maturities net of purchases, while financing provided $1.260 million. Securities maturities move resources between investment and cash classifications; they are not new operating revenue. Management expects resources to support operations into 2027 while retaining substantial going-concern doubt and the need for additional capital. That qualified outlook is different from securing twelve months of funding after the report date. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The insurance-financing note had its final payment in April 2026 and no September balance. A $0.610 million operating lease liability remained, alongside accounts payable and accrued expenses. Merlintrader reading: the absence of that funded note is different from an absence of obligations. The cash needed to settle recorded liabilities and conduct future studies remains part of the operating plan, with payment timing and any further commitments affecting flexibility. September 30, 2026 Form 10-Q, Q2 fiscal 2027

10 ATM financing, warrant changes and capital needs

The current at-the-market (ATM) sales agreement provides a route for common-share sales. At September 30, the company reported $139.2 million of remaining nominal capacity. During the first half of fiscal 2027, it sold 2,794,123 shares for approximately $1.3 million net. From October 1 through November 10 it sold another 595,191 shares for approximately $0.2 million net. The later proceeds and shares are separate subsequent events, not part of the September closing balance. September 30, 2026 Form 10-Q, Q2 fiscal 2027

An ATM is potential sale authority rather than a buyer’s funding commitment. The amount raised depends on actual transactions, market access and contractual or regulatory limits. Merlintrader reading: the headline capacity does not show that a particular trial budget can be raised without materially changing ownership. Net proceeds, timing and any additional security rights determine the usable financing benefit. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The Tranche 1 (T1) warrant series expired in August 2026, removing those instruments as a prospective financing source. All pre-funded warrants had been exercised by September 30. Their underlying shares are already reflected in the capital structure at the relevant dates; the former pre-funded block is not an additional current issuance on top of those shares. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The remaining Tranche 2 (T2) warrants cover 11,265,086 shares, with a contractual $8.877 exercise price and October 4, 2028 expiry. They permit cashless exercise in specified circumstances. A potential future exercise can affect ownership without providing the same amount of cash as a full cash exercise. The contractual strike is a security term, rather than a current market quotation or a guarantee that holders will provide financing. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: the financing assessment requires both sides of the transaction. New cash can preserve a program while increasing the number of shares participating in future value. Existing warrants can add rights and possible issuance, but their maximum nominal proceeds are not cash committed to the development plan. The going-concern assessment and prospective trial scope remain relevant even while an offering framework exists. September 30, 2026 Form 10-Q, Q2 fiscal 2027

T2 holders may elect pre-funded warrants under the exercise terms, and the instruments carry a 9.99% beneficial-ownership limit, with specified adjustment procedures on advance notice. A blocker limits immediate exercisability under its definition; it does not remove the underlying economic rights. The ATM also carries commissions of up to 3%, while offering and listing rules can constrain practical sales. Those terms affect timing, proceeds and legal share issuance independently of the nominal financing ceiling. September 30, 2026 Form 10-Q, Q2 fiscal 2027

11 Share counts, operating reductions and the listing deadline

The latest cover count is 46,186,049 common shares outstanding at November 10, 2026. The September balance sheet reports 45,595,380 issued shares, including 4,522 treasury shares. Issued and outstanding are different concepts, and the later cover date follows subsequent equity activity. Employee awards and warrants represent separate potential interests, subject to their terms rather than automatically adding to legal common outstanding. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The workforce reduction implemented October 26, 2026 affected approximately 31% of the workforce. October 30, 2026 workforce-reduction disclosure The company estimates about $1 million severance and termination cost to be recognized in the quarter ending December 31, 2026 and approximately $3.2 million lower annual salary and benefit costs. These are implementation estimates and a future cost effect, rather than a saving already achieved in the September statements or a complete funding plan for Phase 3. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: a smaller workforce can preserve resources while putting more emphasis on retained capabilities, contractors and focused program selection. Lower salary costs do not make all trial, regulatory and corporate obligations disappear. A new development model needs an operating budget that connects the clinical work with these broader costs. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The company has an additional Nasdaq compliance period through February 1, 2027 under the minimum-bid framework. The deadline is a requirement to regain compliance, rather than an automatic delisting on that date or an announcement that a reverse split has been completed. A reverse split, if undertaken, changes share units and requires its own corporate action; it does not raise operating cash or alter the trial results. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: listing status matters because trading access and financing can be connected. The current requirement and any subsequent notice need to be assessed from their actual terms. Clinical progress and an offering authorization do not independently demonstrate that Nasdaq compliance has been regained. The cost of protecting market access belongs beside the scientific and funding risks. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Outstanding options covered 5,224,425 shares at September 30, including 2,792,339 exercisable. The reported potential-dilutive-securities table also includes the 11,265,086 remaining warrants. These rights are not already issued common shares; their vesting, exercise and settlement rules determine eventual participation. Exclusion from diluted loss per share because they are anti-dilutive does not extinguish the rights or remove future issuance risk. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader calculation: September issued shares of 45,595,380 less 4,522 treasury shares give 45,590,858 outstanding. Adding the subsequent 595,191 ATM shares reconciles to the November 10 cover’s 46,186,049. This bridge distinguishes issued shares, treasury stock and actual later issuance; it is not a hypothetical fully diluted count. Unexercised options and T2 warrants remain separate conditional interests rather than another adjustment to this historical reconciliation. September 30, 2026 Form 10-Q, Q2 fiscal 2027

12 Ownership, governance, legal exposure and short interest

The November 16 BVF and Commodore amendments each report 1,690,014 beneficial shares and approximately 3.7% at September 30. Each position consists entirely of underlying T2 warrants, rather than directly held common shares. The filings use the August 10 common base plus the respective holder’s relevant warrant rights. The two fund groups are separate positions, while entities within each group overlap and are not additional blocks to add. These are dated ownership disclosures, not November common-share purchases or evidence of a clinical opinion. November 16, 2026 BVF Schedule 13G/A November 16, 2026 Commodore Schedule 13G/A

The July 2 Forms 4 report June 30 employee-plan cash acquisitions: 36,818 shares each for CEO Shawn Singh and chief legal officer Reid Adler, and 11,712 for CFO Nick Tressler. They use code A under the employee-plan exemption, rather than code P discretionary open-market buying. The July 31 filing separately reports director Douglas Williamson’s 40,826-option award on July 29. That is compensation for service, not a cash share purchase. July 2, 2026 CEO employee-plan Form 4 July 2, 2026 chief legal officer employee-plan Form 4 July 2, 2026 CFO employee-plan Form 4 July 31, 2026 director option-award Form 4

The October 7 severance amendment extends specified benefits to qualifying terminations without cause outside a change in control, subject to eligibility and release conditions. October 9, 2026 executive-severance amendment disclosure Board and committee composition, severance arrangements and retention decisions are separate governance disclosures. Their financial consequences follow the actual conditions, including the type of termination and vesting provisions. Merlintrader reading: a maximum contractual benefit is different from an amount already paid, while an equity award has potential ownership effects even when its grant-date accounting value is not a cash salary payment. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The Northern District of California action 4:25-cv-01510 was dismissed with prejudice August 12. The current report separately describes Nevada derivative case 2:26-cv-01128 and California securities class action 3:26-cv-00427. California derivative actions 4:26-cv-02656 and 3:26-cv-04480 were consolidated and stayed under the July 30 order. The company disputes the allegations. These are distinct proceedings; one dismissal does not dispose of the other claims, and allegations are different from judicial findings. September 30, 2026 Form 10-Q, Q2 fiscal 2027

The October 30 short-interest settlement data report 2,488,148 shares short, average daily volume 728,036 and published days to cover of 3.42. These describe positioning and historical turnover, rather than current borrowing availability, daily short-sale volume or a mandatory covering date. Merlintrader reading: trading structure can affect sensitivity to news while leaving clinical efficacy and the availability of trial financing unresolved. October 30, 2026 short-interest settlement data

13 Red flags and the evidence behind the assessment

The prospective proof requirement remains. PALISADE-2 met its primary comparison, while three other Phase 3 trials did not. Selected severe-patient findings, repeat-dose exploration and uncontrolled extensions have different evidentiary roles. The current FDA feedback supports further protocol work rather than an approved drug or a completed new trial. November 9, 2026 FDA meeting update September 30, 2026 Form 10-Q, Q2 fiscal 2027

Cash and financing constrain execution. The September report retains substantial going-concern doubt. Workforce reductions can lower costs while imposing transition expense, and ATM capacity is not committed funding. Remaining warrants have cashless provisions and do not provide a certain future cash source. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Portfolio breadth needs prioritization. The other candidates have early clinical signals and possible development routes, while successful future work requires resources and independent evidence. Old upfront receipts and the end of a negotiation period are different from new licensing transactions. Listing compliance and legal obligations add separate execution demands. September 30, 2026 Form 10-Q, Q2 fiscal 2027

Merlintrader reading: Vistagen’s opportunity depends on converting a plausible treatment model into prospectively reproducible clinical benefit and a financed operating plan. The stronger case would connect the revised protocol, a credible budget and adequate controlled evidence. The weaker case would continue generating descriptive analyses without resolving effectiveness or funding. Scientific promise becomes economically more meaningful when the company reduces those uncertainties while preserving an interest for existing shareholders. September 30, 2026 Form 10-Q, Q2 fiscal 2027 November 9, 2026 FDA meeting update

Merlintrader Health Score · $VTGN

1.55out of 5
Balance sheet and runway · 30%1 / 5

Cash and equivalents of $10.892M and securities of $9.142M at September 30 accompany $26.870M of six-month operating cash use. Vistagen reported substantial doubt about going concern.

Catalysts · 30%1.5 / 5

The November 9 update reports FDA feedback on the LSAS and a planned revised protocol. A trial start and funding are pending.

Dilution · 20%1.5 / 5

November 10 common shares were 46,186,049. September quarter ATM sales added 1,213,947 shares. Outstanding warrants and future issuance remain potential dilution.

Trading liquidity · 10%3 / 5

October 30 settlement data report 2,488,148 shares short, average daily volume of 728,036 and 3.42 days to cover. The extension sets February 1, 2027 as the minimum-bid deadline.

Execution · 10%2 / 5

One of four PALISADE Phase 3 trials met its primary endpoint. A revised controlled study would test the proposed broader outcome.

Reassessed November 18, 2026. Merlintrader calculation: 1×30% + 1.5×30% + 1.5×20% + 3×10% + 2×10% = 1.55/5. Fiscal 2027 Q2 filing · November 9 update · Nasdaq extension · October 30 short-interest settlement data. The score describes financial and operating robustness and carries no investment recommendation.

Red flags

  • Three of four PALISADE Phase 3 trials missed their primary endpoint. Controlled evidence.
  • The latest Form 10-Q reports substantial doubt about going concern. Upcoming trials depend on funding and protocol execution. November 13 filing.
  • The extended Nasdaq compliance deadline introduces continued-listing risk. August 4 notice.
  • The latest quarterly filing discusses unresolved litigation. Governance and legal matters.

VTGN Stock FAQ: Vistagen Therapeutics, Inc. Questions Answered

When is the next VTGN stock catalyst?

Vistagen’s Nasdaq compliance deadline is February 1, 2027, under its August 4, 2026 disclosure. On November 9, 2026, after a Type C meeting, Vistagen said it plans to submit a revised Phase 3 protocol reflecting FDA feedback on the LSAS endpoint and interim assessments; the trial remains subject to financing, with no confirmed start or readout date. November 9 regulatory update. Nasdaq extension and requirements. Proposed clinical development plan.

Is Vistagen’s fasedienol FDA approved?

No: Vistagen’s September 2026 development materials describe investigational fasedienol and a proposed additional social-anxiety trial; after FDA Type C feedback, Vistagen said on November 9 that it plans to submit a revised protocol. PALISADE-2 met its primary endpoint with 141 randomized participants, while PALISADE-1, -3 and -4 did not. Exploratory and open-label results do not change those prospective primary outcomes. Development status and proposed trial. PALISADE outcomes.

How much cash does Vistagen have, and how long will it last?

Vistagen reported $10.892 million in cash and equivalents and $9.142 million in marketable securities at September 30, 2026. Vistagen expects funding into 2027 and the filing states substantial doubt about going concern. Operating cash use was $26.870 million over the six months ending September 30. Fiscal 2027 Q2 Form 10-Q · November 13 outlook.

Is VTGN stock at risk of dilution?

Yes: Vistagen reported 46,186,049 common shares on November 10, 2026, against 44,376,911 on August 10, with equity awards, warrants and potential ATM issuance adding exposure. The September-quarter filing states about $139.2 million of remaining nominal ATM capacity at September 30. September-quarter Form 10-Q. That capacity requires future sales and is not committed financing or cash available to spend. Outstanding shares, equity instruments and ATM.

When does Vistagen report earnings?

Vistagen reported the quarter ended September 30, 2026, the second quarter of fiscal 2027, on November 13. As of November 18, 2026, the company had not announced its next financial reporting date. September-quarter filing · November 13 results.

What does Vistagen Therapeutics do?

Vistagen develops investigational treatments for central nervous system conditions. Its lead candidate fasedienol is a nasal pherine being developed for social anxiety disorder. Other clinical candidates include itruvone for major depressive disorder and refisolone for menopausal hot flashes. Company development priorities.

Did Vistagen’s PALISADE-4 meet its primary endpoint?

PALISADE-4 missed its primary endpoint, as reported on June 30, 2026. The November 9 update says the next proposed study would assess overall social anxiety disorder using the LSAS, subject to a revised protocol. June 30 PALISADE-4 results · November 9 update.

Will Vistagen automatically be delisted on February 1, 2027?

No: Vistagen’s August 4, 2026 filing describes February 1, 2027 as the extended deadline to regain bid-price compliance. The stated route generally requires a closing bid of at least $1 for ten consecutive business days. Failure could lead to a delisting notice with a hearing or appeal process, rather than automatic removal on that date. Compliance and subsequent Nasdaq process.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $VTGN or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, official trial registries, regulatory agency documents and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a regulatory filing or a results release become outdated the moment the outcome is announced. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, a proposed registrational pathway may not be accepted by the agency, a listing deficiency can end in delisting, and further financing may depend on market conditions and entail material dilution. A single decision can change the value of the business overnight in either direction. Every reader is responsible for their own decisions and should do their own research and consult a licensed or authorised financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.